Development of a vaccine to prevent chlamydia

Chlamydia − the most common sexually transmitted infection (STI) in the world, which is diagnosed in about 1 billion people, every 7th inhabitant of the planet.

Unlike gonorrhea, which is a typical STI, the symptoms of chlamydia are less pronounced, the incubation period is longer, and complications occur more frequently.

For more information about the complications, modern methods of diagnosis, treatment and prevention of chlamydia, read the article on estet-portal. com.

• Development of Chlamydia Prevention Methods
• Objects and methods of research on the prevention of chlamydia
• Chlamydia vaccine efficacy resultsfor

Development of Chlamydia Prevention Methods

The most serious complications of chlamydia in women include pelvic inflammatory disease:

• endometritis;
• salpingitis;
• salpingoophoritis.

These diseases pose a serious threat to women's reproductive health.

Follow us on Instagram!

Children born to infected women often have chlamydial inflammation of the eyes and lungs after birth.

In infected men, chlamydia causes inflammation of the urethra and testicles (orchitis), which is a common cause:

• prostatitis;
• infertility;
• chronic inflammation of the joints (Reiter's disease).

Unknown cause of male infertility? We suspect chlamydia

Scientists have long been concerned about the prevention of chlamydia − how to reduce the incidence or eradicate this infection from the population.

The most common chlamydia prevention methods include:

1. Educational activities for the prevention of chlamydia − relate to informing the population about protection during sexual intercourse.

Resources become the main issue: where to find qualified specialists who can motivate young people to take care of themselves and their partner.

2. Screening programs for the diagnosis and prevention of chlamydia followed by antibiotic therapy.

Both methods have a very limited effect: according to WHO, more than 100 million new cases of infection with Chlamidia trachomatis.

Therefore, the issue of creating a vaccine for the prevention of chlamydia has been discussed for more than a year. After all, the struggle of the oldmy methods is ineffective.

Objects and methods of research on the prevention of chlamydia

Scientists at the Hammersmith Hospital in London, UK, have completed a I phase study of recombinant subunit vaccines against the chlamydia pathogen.

The study involved 40 women aged 19-40 years, 30 women received a vaccine with a liposomal adjuvant or aluminum hydroxide adjuvant.

Five women received placebo − sodium chloride solution.

Genital herpes: the main drugs for the treatment of the disease

Vaccination was carried out in several stages: women received intramuscular injections at a dose of 85 mcg into the deltoid muscle of the arm at 0-, 1- and 4th months.

The women then received the vaccine in the form of an intranasal spray − 30 mcg in each nostril for the 4th and 5th monthsce. 

Chlamydia vaccine efficacy results

32 women completed the course of vaccination. No cases of serious complications were noted.

The most common complication was a local inflammatory reaction at the injection site, in other words, redness.

It was noted in all women who were instilled with the "real" vaccine, as well as three out of five after injection of sodium chloride solution.

Both vaccines showed 100% result: seroconversion with the appearance of IgG in blood plasma.

The liposomal adjuvanted vaccine was more successful, resulting in high IgG titers and seroconversion rates, a better mucosal antibody profile, and a stable immune response compared to aluminum hydroxide.

The placebo group (sodium chloride solution) showed zero seroconversion (p = 00526).

Reiter's Syndrome: what is the danger of a complex extragenital complication

Study results indicate that vaccination is effective and safe for preventing chlamydia.

Both vaccines produce the necessary immune response, however the liposomal adjuvanted vaccine is superior to its aluminum hydroxide counterpart.

Further, larger studies should prove the long-term efficacy of vaccination in preventing chlamydia.

Share: